Home » Newsletters » BioWorld Science

BioWorld Science

June 28, 2022

View Archived Issues

ON-203, a second-generation anti-oxMIF antibody with improved efficacy

RAC1 variants found to cause a novel developmental syndrome

LETM1 causes mitochondrial osmotic dysregulation tied to pathology

MagicMed Industries discloses new 5-HT2A receptor agonists

Suzhou Vincentage Pharma patents GLP-1 receptor agonists

Targeting of CD46 allows PET imaging of mesothelioma with [89Zr]DFO-YS5

Chengdu Easton Biopharmaceuticals discloses BET inhibitors

Chinese researchers identify new JAK1 inhibitors

IMPACT Therapeutics synthesizes new NUAK inhibitors

RBM22 inversely correlates with prostate cancer aggressiveness

EAN 2022: At several scales, connective landscape provides lens for neurology

New pH-responsive albumin-binding ligands show targeted tumor uptake in vivo

Use of [89Zr]Prot-FH for neutrophil imaging during fungal infection

Ainos reports preclinical data on low-dose oral interferon-alpha Veldona against COVID-19

Hillstream partners with Sapien to study synergy between HSB-1216 and immune checkpoint inhibitors

NCI grant supports Penn's development of intraoperative imaging technology for NSCLC

Kuria licenses rights to SCOHIA's SCO-116 for ocular and dermatologic diseases

Astellas and Sutro partner to discover and develop novel immunostimulatory antibody-drug conjugates

Ideaya selects Pol Theta Helicase development candidate

Confo awarded grant to support GPCR drug discovery

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 17, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 17, 2025.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...